AR and prostate cancer: We recently reported that a clinically applied androgen receptor (AR) antagonist, bicalutamide (Bic), exhibits chromatin remodeling activity, with a gene expression profile different from that induced by an active androgen (dihydrotestosterone [DHT]), in human prostate cancer cells (LNCaP) expressing endogenous AR [33].